Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (275)	3/25/1999 12:26:00 PM
From: scaram(o)uche	Respond to of 3559

Message 8500367 Message 8501071

To: scaram(o)uche who wrote (275)	3/25/1999 8:48:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

Richard: <<We seem to have four classes of CEOs in biotech right now.....>> Tell me about! :( But, not only CEOs. All upper pyramidal power structure at bts are going to this classes. CEO sometime move the string as others dictate. Hey, they also have family to feet. This is about to chance, as no more free financing is available. Unfortunately, in all this mess good bts also pay the price. REGN, with its leverage plan (P&G pay for >80% R&D expense and all early clinical trials) have excepted this trap (no needs for fresh cash), but they didn't excepted overall down trend in bt sector of the small caps. Also, REGN was very quite for last two Q. I can't believe that there is nothing going worth to inform as, small investors. REGN should spill something out, or we are at mercy of the shorts. Any idea is REGN presenting at AACR meeting? Angio-2 and MAP-kinases are related to cancer therapy research, but I didn't catch any new development in this area. Cheers, Miljenko